Zevra Therapeutics (NASDAQ:ZVRA) Price Target Cut to $18.00 by Analysts at Guggenheim

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) had its price target dropped by analysts at Guggenheim from $23.00 to $18.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s price objective would indicate a potential upside of 98.24% from the stock’s current price.

A number of other equities analysts have also commented on ZVRA. Weiss Ratings restated a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Citizens Jmp boosted their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. Finally, BTIG Research cut their price objective on shares of Zevra Therapeutics from $24.00 to $21.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $23.86.

Get Our Latest Stock Analysis on Zevra Therapeutics

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $9.08 on Monday. The company’s 50 day moving average price is $10.99 and its two-hundred day moving average price is $10.83. Zevra Therapeutics has a 12-month low of $8.01 and a 12-month high of $15.03. The firm has a market cap of $540.31 million, a PE ratio of 7.63 and a beta of 1.01.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%. The company had revenue of $37.76 million for the quarter, compared to analysts’ expectations of $37.08 million. On average, research analysts expect that Zevra Therapeutics will post 0.88 EPS for the current year.

Insiders Place Their Bets

In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer directly owned 417,225 shares in the company, valued at $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently modified their holdings of ZVRA. Integrated Wealth Concepts LLC acquired a new position in Zevra Therapeutics during the second quarter worth about $28,000. Fulcrum Asset Management LLP acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $33,000. State of Alaska Department of Revenue bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at approximately $44,000. Finally, State of Wyoming bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at approximately $81,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.

See Also

Analyst Recommendations for Zevra Therapeutics (NASDAQ:ZVRA)

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.